An autonomous AI agent integrating Reasoning and Acting with Retrieval-Augmented Generation with Retrieval-Augmented Generation is developed to classify 10,211 Human Phenotype Ontology terms, enabling standardized panel design by providing reliable, automated classification supported by direct evidence.
Abstract
Disease severity classification for genetic conditions is subjective and labor-intensive, creating bottlenecks in genomic screening, where commercial panels vary widely in size and overlap. We developed an autonomous AI agent integrating Reasoning and Acting (ReAct) with Retrieval-Augmented Generation (RAG) to classify 10,211 Human Phenotype Ontology terms. It uses American College of Medical Genetics (ACMG)-endorsed severity guidelines and American College of Obstetricians and Gynecologists (ACOG) quality-of-life criteria to retrieve PubMed literature, generate interpretable reasoning chains, and independently verify claims. At the phenotype level, using expert-curated cohorts, the agent achieved 93.55% accuracy (MCC 0.9237) with 82.6% to 91.4% of claims supported by direct evidence or valid inferences. Gene-level severity was aggregated across 8,738 pairs, identifying 3,283 autosomal recessive pairs with severe or profound presentations. External validation showed 95.2% concordance with Mackenzie's Mission gene list. This system enables standardized panel design by providing reliable, automated classification supported by direct evidence.
aiDIVA is presented, an ensemble-AI combining statistical and machine learning models trained on genomic and phenotypic data to identify causal variants among tens of thousands per patient, and applies a random forest model to classify pathogenicity and generates evidence-based scores for dominant and recessive disease...
D. Boceck, L. Laugwitz, M. Sturm et al.· npj Genomic Medicine· 1 citation
Background Phenotype-genotype associations underpin precision medicine by enabling disease prevention, early diagnosis, risk stratification, therapeutic target discovery, and personalized treatment. However, the rapid growth of scientific evidence has made manual curation of these associations increasingly labor-intens...
Caiwan Sun, Yi Xin, Sarah Zeng et al.· bioRxiv· 0 citations
A novel domain-grounded instruction framework is developed to systematically evaluate GPT-5 for producing genetic evidence relevant to clinical trial success and introduces TigerAI, a dual-purpose platform for AI-powered genetic evidence that benchmarks emerging state-of-the-art LLMs and provides an accessible service...
Zi-Chen Zhang, Wan-Heng Zhang, Xiao-Chen Yang et al.· bioRxiv· 0 citations
INTRODUCTION
Accurate interpretation of clinical trial eligibility criteria is essential for applications such as patient-trial matching and clinical decision support, particularly in precision oncology. However, relevant information, including genetic mutation requirements, is typically embedded in unstructured text w...
Georg Mathes, S. Berger, Stefan Sigle· Studies in Health Technology...· 0 citations
Genetic prediction of clinically defined disease subtypes could advance precision medicine, but polygenic risk scores (PRSs) often show limited ability to distinguish subtypes, either because the subtypes share genetic architecture or because available PRSs are inaccurate. We introduce GenSep, a statistical framework t...
HeartVar demonstrates that an LLM constrained by a domain-specific prompt and grounded in structured evidence can produce variant interpretations of first-pass quality for a cardiovascular disease cohort; however, it is not intended to replace manual assessment by a qualified variant curator.
Jamie-Lee M. Thompson, Debjani Das, Sally L. Dunwoodie et al.· bioRxiv· 0 citations